3 Dec 2020 09:45
Director Dealing
3rd December 2020
LONDON, Silence Therapeutics plc, AIM:SLN and Nasdaq: SLN ("Silence" or "the Company"), a leader in the discovery, development and delivery of novel short interfering ribonucleic acid (siRNA) therapeutics for the treatment of diseases with significant unmet medical need, today announces that, on the 30th November 2020, 4,500 Shares were purchased by Dr. Steven Romano, Non-Executive Director of the Company, at $5.58 per share.
Following this purchase, Dr. Steven Romano is interested in 14,500 ordinary shares (0.02%) of the issued share capital of the Company.
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them
1. | Details of the person discharging managerial responsibilities (PDMR) / person closely associated | |||||||||||||
a) | Name | Dr. Steven Romano
| ||||||||||||
2. | Reason for the notification | |||||||||||||
a) | Position / status | Non-Executive Director
| ||||||||||||
b) | Initial notification / Amendment | Initial notification | ||||||||||||
3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||||||||||
a) | Name | Silence Therapeutics plc
| ||||||||||||
b) | LEI | 213800SSURRJBX85SQ91
| ||||||||||||
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||||||||||
a) | Description of the financial instrument, type of instrument
Identification code | Ordinary Shares of 5 pence each in Silence Therapeutics plc
ISIN for Silence Therapeutics plc Ordinary Shares: GB00B9GTXM62
| ||||||||||||
b) | Nature of the transaction | Purchase of Ordinary Shares in Silence Therapeutics plc
| ||||||||||||
c) | Prices(a) and volume(s) |
| ||||||||||||
d) | Aggregated information - Aggregated volume - Price | Aggregate Volume: 4,500 shares Metric for Quantity: Shares Aggregated Volume Price per share: $5.5806
| ||||||||||||
e) | Date of the transaction | 30 November 2020 (Time zone: Eastern Standard Time) | ||||||||||||
f) | Place of the transaction | Outside a trading venue
| ||||||||||||
Enquiries:
Silence Therapeutics plc Gem Hopkins, Head of IR & Corporate Communications | Tel: +1 (646) 637-3208 |
Investec Bank plc (Nominated Adviser and Broker) Daniel Adams/Gary Clarence
|
Tel: +44 (0) 20 7597 5970 |
European IR Consilium Strategic Communications Mary-Jane Elliott/Chris Welsh/Angela Gray silencetherapeutics@consilium-comms.com
| Tel: +44 (0) 20 3709 5700 |
US IR Westwicke Partners Peter Vozzo peter.vozzo@westwicke.com
| Tel: +1 (443) 213-0505 |
About Silence Therapeutics plc
Silence Therapeutics is developing a new generation of medicines by harnessing the body's natural mechanism of RNA interference, or RNAi, to inhibit the expression of specific target genes thought to play a role in the pathology of diseases with significant unmet medical need. Silence's proprietary technology can be used to engineer short interfering ribonucleic acids (siRNAs) that bind specifically to and silence, through the RNAi pathway, almost any gene in the human genome to which siRNA can be delivered. Silence's wholly owned product candidates include SLN360 designed to address the high and prevalent unmet medical need in reducing cardiovascular risk in people born with high levels of Lipoprotein(a) and SLN124 to address beta-thalassemia and myelodysplastic syndrome. Silence is also developing a C3 targeting programme, SLN500, in partnership with Mallinckrodt Pharmaceuticals to reduce the expression of the C3 protein for the treatment of complement pathway-mediated diseases. Silence maintains ongoing research and collaborations with AstraZeneca, Mallinckrodt Pharmaceuticals and Takeda. For more information, please visit: https://www.silence-therapeutics.com/